And so it begins. In 6, 7, 8 or 9 months time, depending on how fast they dosed the patients, we will know the outcome of the primary endpoint. If the outcome is better than Keytruda/chemo alone in terms of efficacy, safety and tolerability, Merck will pounce with a deal.
I am not too sure about this but they could likely present to FDA for fast track to market. In other words, Hervaxx could well go to market by second half of next year as a combination treatment with Keytruda.
Ann: Imugene doses first patient in nextHERIZON Phase 2 trial, page-13
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
0.001(2.22%) |
Mkt cap ! $342.1M | |||
| Open | High | Low | Value | Volume |
| 4.5¢ | 4.7¢ | 4.5¢ | $906.2K | 19.67M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 9543864 | 4.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.6¢ | 1266571 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |